Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Five Technology Stocks That Hedge Funds Bought Last Month

The Technology sector has always represented an area of interest for investors. Actually, as we stated earlier, during the fourth quarter of 2013, three of the ten most popular stocks among hedge funds, have been technology companies: Apple Inc. (NASDAQ:AAPL), Google Inc (NASDAQ:GOOG), and Microsoft Corporation (NASDAQ:MSFT).

During the previous month, hedge funds have been active and have increased or reduced holdings from their equity portfolios. Several of these moves involved technology stocks. In this piece we would like to take a look back and check out what have been some of the technology companies that hedge funds bought during March.

Elliott Management Corporation, led by Paul Singer, has around a third of its $4.4 billion equity portfolio held in the Technology sector. During the last month, Elliott revealed surging its position in Juniper Networks, Inc. (NYSE:JNPRto 36.9 million shares, from just some 2.6 million held previously. In this way, Mr. Elliott currently controls 7.4% of the company’s stock. Moreover, Mr. Singer is planning to acquire Riverbed Technology, Inc. (NASDAQ:RVBD), and sent a letter to the company’s board accusing them of not pursuing the best interests for shareholders. The investor, which currently holds 10.5% of Riverbed’s outstanding stock, and plans to buy the rest of the shares for $21 apiece.

Paul Singer ELLIOTT MANAGEMENT

Another hedge fund, John Lykouretzos‘ Hoplite Capital Management has been bullish on the photovoltaic energy solutions company Sunedison Inc (NYSE:SUNE). The fund has initiated a position in the company, which contains around 16 million shares, equal to 6% of the common stock. Billionaires Steven Cohen and Leon Cooperman are also fond of this company and held 12.80 million shares and 8.1 million shares at the end of 2013.

RealPage, Inc. (NASDAQ:RP), an enterprise software company focused on the rental housing segment, has received some interest from Berkshire Partners’ subsidiary Stockbridge Partners, managed by Robert J. Small. Stockbridge almost doubled its stake in the company to 4.05 million shares, equal to 5.2% of the outstanding stock, from 2.16 million held previously.

Bob Peck and Andy Raab‘s FPR Partners has picked up its position in ViaSat, Inc. (NASDAQ:VSATtaking it to 4.81 million shares, from 4.55 million held previously. The new position amasses 10.4% of the company’s stock. ViaSat is a $3.2 billion market cap company engaged in satellite and other wireless networks.

Last but not least, Altai Capital, a fund managed by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has added slightly below 1.0 million shares to its stake in Vocus, Inc. (NASDAQ:VOCS), a small cap provider of cloud marketing software. Currently, Altai Capital holds 2.5 million shares of Vocus, which account for 11.6% of the stock. Altai has a relatively small equity portfolio, worth around $370.8 million, but around 70% of the portfolio are represented by Technology stocks.

Disclosure: none

Recommended Reading:

Top Hedge Fund Moves During March

Elliott Management Wagers on Boyd Gaming Corp. (BYD)

Stockbridge Partners’ Latest Stock Moves

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!